SBRT 2016

Systematic review of SBRT for centrally located NSCLC

Publications

22

Centrally located tumors

563 315 ≧ 85% 9%

Stage I NSCLC

≧ 100 Gy

 LC for BED

 G 3 / 4 toxicity

 Overall Tx related mortality  Tx related mortality BED <210Gy

2.7% 1.0%

8 x 7.5Gy 3 x 13Gy • Acceptable therapeutic ratio of more fractionated SBRT 5 x 10Gy

M Guckenberger - SBRT stage I NSCLC - HICARE 2015

22

/